RCUS (Arcus Biosciences) Short Interest


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $28.80
GF Value $13.85
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RCUS vs TNGX, DYN, RLAY: Short Interest Comparison

For the Biotechnology subindustry, Arcus Biosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcus Biosciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's Short Interest falls into.


RCUS
46GF Score
Arcus Biosciences Inc RCUS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $28.80 is trading 107.9% above its estimated GF Value™ of $13.85. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • Short Interest:
  • GF Value™: $13.85 vs. price of $28.80 (107.9% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.80
Price
$13.85
GF Value